STAT

Did he really just tweet that? Dr. Vinay Prasad takes on Big Pharma, Big Medicine, and his own colleagues — with glee

Dr. Vinay Prasad crusades for the principle that scientific evidence, not hope or hype, should guide medical practice. He's made plenty of enemies.

PORTLAND, Ore. — Dr. Vinay Prasad is a professional scold: He takes to Twitter each day to critique this cancer drug as ineffective, or blast that one as overpriced, or dismiss the clinical trial of another as completely irrelevant.

So it’s a bit of a surprise to catch him at the bedside of an elderly man with lymphoma, laughing gently with his patient as he inquires about his day — and painstakingly explains a potent drug’s unpleasant side effects.

Prasad’s empathic bedside manner — and generally affable mien — is at stark odds with his digital persona as a caustic crusader for the principle that solid scientific evidence, not hope or hype, should guide how we as a society spend $700 billion a year on health care.

Just 34, Prasad has become an influential voice in the medical community through his prolific, high-impact publishing, a steady stream of media cameos, and — of course — his vociferous Twitter presence. Among his main arguments: Drug costs have spiraled out of control. Conflicts of interest run amok in health care. We don’t have any idea how well new cancer drugs and diagnostics work, thanks to ill-designed clinical trials. And more than half of all practiced medicine is based on scant evidence — and possibly ineffectual.

Needless to say, such positions haven’t won him many close friends among pharma companies — or even among some fellow doctors. He doesn’t much care.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks